https://news.medxy.ai/zh/80880-2/Medxy AIzh2026-10-05T06:21:25-07:00为期8周的Bemnifosbuvir-Ruzasvir疗法：治疗慢性丙型肝炎疗效高且耐受性良好 https://news.medxy.ai/ja/80879-2/Medxy AIja2026-10-05T06:21:03-07:00ベムニフォスブビル・ルザスビル8週間投与レジメン：慢性C型肝炎における高い有効性と良好な忍容性 https://news.medxy.ai/vi/bemnifosbuvir-ruzasvir-8-weeks/Medxy AIvi2026-10-05T06:20:38-07:00Phác đồ Bemnifosbuvir–Ruzasvir 8 Tuần: Hiệu Quả Cao và Dung Nạp Tốt trong Viêm Gan C Mạn https://news.medxy.ai/high-efficacy-and-tolerability-of-an-8-week-bemnifosbuvir-and-ruzasvir-regimen-in-chronic-hepatitis-c-insights-from-a-phase-2-study/Medxy AIen2026-10-05T06:20:17-07:00High Efficacy and Tolerability of an 8-Week Bemnifosbuvir and Ruzasvir Regimen in Chronic Hepatitis C: Insights from a Phase 2 Study https://news.medxy.ai/zh/ctdna-colorectal-cancer/Medxy AIzh2026-10-05T06:19:33-07:00借助循环肿瘤 DNA 识别结直肠癌微小残留病灶：INTERCEPT 计划的研究启示 https://news.medxy.ai/ja/colon-cancer-ctdna/Medxy AIja2026-10-05T06:19:13-07:00大腸癌の微小残存病変検出における循環腫瘍DNAの活用：INTERCEPTプログラムからの知見 https://news.medxy.ai/vi/80873-2/Medxy AIvi2026-10-05T06:18:52-07:00Phát hiện bệnh tồn dư tối thiểu trong ung thư đại trực tràng bằng DNA khối u lưu hành: Những hiểu biết từ chương trình INTERCEPT https://news.medxy.ai/harnessing-circulating-tumour-dna-for-minimal-residual-disease-detection-in-colorectal-cancer-insights-from-the-intercept-programme/Medxy AIen2026-10-05T06:18:29-07:00Harnessing Circulating Tumour DNA for Minimal Residual Disease Detection in Colorectal Cancer: Insights from the INTERCEPT Programme https://news.medxy.ai/an-unexpected-cause-of-severe-steatohepatitis-in-a-young-male/Medxy AIen2026-10-05T06:17:44-07:00An Unexpected Cause of Severe Steatohepatitis in a Young Male https://news.medxy.ai/ja/ems-stroke-guidelines/Medxy AIja2026-10-05T06:17:03-07:00通常EMSにおける院前脳卒中試験の運営・倫理・技術上の優先事項：専門家コンセンサスの解説 https://news.medxy.ai/vi/stroke-trial-priorities/Medxy AIvi2026-10-05T06:16:29-07:00Ưu tiên vận hành, đạo đức và công nghệ cho các thử nghiệm đột quỵ trước viện trong EMS thường quy: Giải thích đồng thuận chuyên gia https://news.medxy.ai/zh/ems-stroke-trial/Medxy AIzh2026-10-05T06:15:49-07:00常规EMS院前卒中试验的操作、伦理与技术优先事项：专家共识解读 https://news.medxy.ai/operational-ethical-and-technological-priorities-for-prehospital-stroke-trials-in-conventional-ems-an-expert-consensus-explained/Medxy AIen2026-10-05T06:15:19-07:00Operational, Ethical, and Technological Priorities for Prehospital Stroke Trials in Conventional EMS: An Expert Consensus Explained https://news.medxy.ai/zh/80863-2/Medxy AIzh2026-10-05T06:14:09-07:00急性缺血性脑卒中患者接受血管内血栓切除术后肌酐水平的连续变化与预后有关 https://news.medxy.ai/ja/creatinine-change-stroke/Medxy AIja2026-10-05T06:13:42-07:00閾値を超えて：急性虚血性脳卒中に対する血管内血栓除去術後の連続的クレアチニン変化と転帰 https://news.medxy.ai/vi/80861-2/Medxy AIvi2026-10-05T06:13:15-07:00Diễn biến nồng độ creatinine liên tục và kết cục lâm sàng sau thủ thuật lấy huyết khối qua đường nội mạch ở bệnh nhân đột quỵ thiếu máu cục bộ cấp tính https://news.medxy.ai/beyond-the-threshold-continuous-creatinine-change-and-outcomes-after-endovascular-thrombectomy-for-acute-ischemic-stroke/Medxy AIen2026-10-05T06:12:46-07:00Beyond the Threshold: Continuous Creatinine Change and Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke https://news.medxy.ai/zh/left-atrial-appendage-occlusion-2/Medxy AIzh2026-10-05T06:11:51-07:00心房颤动卒中预防中左心耳封堵与口服抗凝治疗之比较：最新 Meta 分析 https://news.medxy.ai/ja/80857-2/Medxy AIja2026-10-05T06:11:30-07:00心房細動に伴う脳卒中予防における左心耳閉鎖術と経口抗凝固療法の比較 https://news.medxy.ai/vi/80856-2/Medxy AIvi2026-10-05T06:11:08-07:00So sánh giữa thủ thuật đóng tiểu nhĩ trái và liệu pháp dùng thuốc chống đông đường uống để phòng ngừa đột quỵ ở bệnh nhân rung nhĩ https://news.medxy.ai/evaluating-left-atrial-appendage-closure-versus-oral-anticoagulation-for-stroke-prevention-in-atrial-fibrillation-an-updated-meta-analysis/Medxy AIen2026-10-05T06:10:45-07:00Evaluating Left Atrial Appendage Closure Versus Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: An Updated Meta-Analysis https://news.medxy.ai/zh/tbi-life-support-trends/Medxy AIzh2026-10-05T06:10:04-07:00创伤性脑损伤患者维持生命治疗撤除趋势变化：基于ACS创伤数据十年研究的启示 https://news.medxy.ai/ja/life-support-withdrawal-trends/Medxy AIja2026-10-05T06:09:47-07:00外傷性脳損傷患者における生命維持治療中止の推移：ACS外傷データ10年解析からの示唆 https://news.medxy.ai/vi/tbi-treatment-trends/Medxy AIvi2026-10-05T06:09:21-07:00Xu hướng thay đổi trong việc rút lui điều trị duy trì sự sống ở bệnh nhân chấn thương sọ não: Góc nhìn từ dữ liệu chấn thương ACS trong 10 năm https://news.medxy.ai/evolving-patterns-in-withdrawal-of-life-sustaining-treatment-among-traumatic-brain-injury-patients-insights-from-a-decade-of-acs-trauma-data/Medxy AIen2026-10-05T06:08:58-07:00Evolving Patterns in Withdrawal of Life-Sustaining Treatment Among Traumatic Brain Injury Patients: Insights From a Decade of ACS Trauma Data https://news.medxy.ai/zh/skin-denervation-parkinsons/Medxy AIzh2026-10-05T06:08:18-07:00皮肤去神经支配：连接帕金森病认知下降与脑萎缩的新型生物标志物 https://news.medxy.ai/ja/skin-denervation-parkinson/Medxy AIja2026-10-05T06:07:59-07:00皮膚脱神経はパーキンソン病の認知低下と脳萎縮を示すバイオマーカーとなり得る https://news.medxy.ai/vi/skin-neuropathy-parkinson/Medxy AIvi2026-10-05T06:07:36-07:00Mất chi phối thần kinh ở da: dấu ấn sinh học liên quan đến suy giảm nhận thức và teo não trong bệnh Parkinson https://news.medxy.ai/skin-denervation-as-a-biomarker-linked-to-cognitive-decline-and-brain-atrophy-in-parkinson-disease/Medxy AIen2026-10-05T06:07:13-07:00Skin Denervation as a Biomarker Linked to Cognitive Decline and Brain Atrophy in Parkinson Disease https://news.medxy.ai/zh/car-t-cns-lymphoma/Medxy AIzh2026-10-05T06:06:34-07:00CAR T细胞治疗后，中枢神经系统淋巴瘤患者的中期认知结局：急性神经毒性之外的积极证据 https://news.medxy.ai/ja/car-t-therapy-cns-lymphoma/Medxy AIja2026-10-05T06:06:15-07:00CNSリンパ腫に対するCAR T細胞療法後の中期認知機能：急性神経毒性を超えて見えてきた有望な知見 https://news.medxy.ai/vi/car-t-therapy-lymphoma-3/Medxy AIvi2026-10-05T06:05:53-07:00Sau liệu pháp CAR T ở bệnh nhân u lympho hệ thần kinh trung ương: bằng chứng đáng khích lệ về chức năng nhận thức trung hạn vượt qua độc tính thần kinh cấp tính https://news.medxy.ai/midterm-cognitive-outcomes-after-car-t-cell-therapy-in-cns-lymphoma-patients-encouraging-evidence-beyond-acute-neurotoxicity/Medxy AIen2026-10-05T06:05:30-07:00Midterm Cognitive Outcomes After CAR T-Cell Therapy in CNS Lymphoma Patients: Encouraging Evidence Beyond Acute Neurotoxicity https://news.medxy.ai/zh/sar443820-als-efficacy/Medxy AIzh2026-10-05T06:04:52-07:00SAR443820 在肌萎缩侧索硬化中的疗效评估：来自 HIMALAYA 2 期试验的启示 https://news.medxy.ai/ja/als-ripk1-inhibitor/Medxy AIja2026-10-05T06:04:28-07:00ALSにおけるRIPK1阻害薬SAR443820を評価する：第2相HIMALAYA試験から得られた知見 https://news.medxy.ai/vi/80836-2/Medxy AIvi2026-10-05T06:04:02-07:00Đánh giá thuốc ức chế RIPK1 SAR443820 trong bệnh ALS: Những hiểu biết từ thử nghiệm HIMALAYA giai đoạn 2 https://news.medxy.ai/evaluating-sar443820-a-ripk1-inhibitor-in-amyotrophic-lateral-sclerosis-insights-from-the-phase-2-himalaya-trial/Medxy AIen2026-10-05T06:03:42-07:00Evaluating SAR443820, a RIPK1 Inhibitor, in Amyotrophic Lateral Sclerosis: Insights from the Phase 2 HIMALAYA Trial https://news.medxy.ai/zh/apolipoprotein-j-kidney-damage-2/Medxy AIzh2026-10-05T05:31:44-07:00肝源性载脂蛋白J通过破坏TFEB介导的脂质调控驱动糖尿病肾损伤 https://news.medxy.ai/ja/80827-2/Medxy AIja2026-10-05T05:31:25-07:00肝臓由来アポリポタンパク質Jは、TFEBを介した脂質制御の破綻を通じて糖尿病性腎障害を惹起する https://news.medxy.ai/vi/apolipoprotein-j-kidney-damage/Medxy AIvi2026-10-05T05:31:03-07:00Apolipoprotein J từ gan thúc đẩy tổn thương thận do đái tháo đường qua rối loạn điều hòa lipid trung gian TFEB https://news.medxy.ai/liver-derived-apolipoprotein-j-drives-diabetic-kidney-injury-by-disrupting-tfeb-mediated-lipid-regulation/Medxy AIen2026-10-05T05:30:42-07:00Liver-Derived Apolipoprotein J Drives Diabetic Kidney Injury by Disrupting TFEB-Mediated Lipid Regulation https://news.medxy.ai/zh/empagliflozin-vs-dapagliflozin/Medxy AIzh2026-10-05T05:30:03-07:00Empagliflozin与Dapagliflozin谁更护肝？韩国大队列研究给出答案 https://news.medxy.ai/ja/80815-2/Medxy AIja2026-10-05T05:29:43-07:00エンパグリフロジンとダパグリフロジン、どちらがより肝臓を保護するのか？韓国の大規模コホート研究が答えを提示 https://news.medxy.ai/vi/empagliflozin-vs-dapagliflozin-liver/Medxy AIvi2026-10-05T05:29:21-07:00So sánh trực tiếp empagliflozin và dapagliflozin về kết cục gan ở đái tháo đường type 2 kèm MASLD https://news.medxy.ai/head-to-head-comparison-of-empagliflozin-and-dapagliflozin-on-liver-outcomes-in-type-2-diabetes-with-masld/Medxy AIen2026-10-05T05:28:57-07:00Head-to-Head Comparison of Empagliflozin and Dapagliflozin on Liver Outcomes in Type 2 Diabetes with MASLD https://news.medxy.ai/zh/type-2-diabetes-management/Medxy AIzh2026-10-05T05:17:09-07:002型糖尿病血糖管理再升级：数字疗法联合CGM带来更优结局 https://news.medxy.ai/ja/type-2-diabetes-management-2/Medxy AIja2026-10-05T05:16:49-07:002型糖尿病の血糖管理をさらに前進：CGM併用デジタル治療でより良好な転帰 https://news.medxy.ai/vi/better-blood-sugar-control/Medxy AIvi2026-10-05T05:16:29-07:00Kiểm soát đường huyết tốt hơn ở đái tháo đường type 2: Dược phẩm số phối hợp CGM cho kết quả vượt trội https://news.medxy.ai/enhanced-glycaemic-control-in-type-2-diabetes-digital-therapeutics-combined-with-cgm-show-superior-outcomes/Medxy AIen2026-10-05T05:16:10-07:00Enhanced Glycaemic Control in Type 2 Diabetes: Digital Therapeutics Combined with CGM Show Superior Outcomes https://news.medxy.ai/zh/cabergoline-prolactinoma-treatment/Medxy AIzh2026-10-05T05:15:28-07:00最低泌乳素水平指导的卡麦角林治疗：推动垂体催乳素瘤的持久缓解与安全妊娠 https://news.medxy.ai/ja/cabergoline-treatment/Medxy AIja2026-10-05T05:15:07-07:00最低プロラクチン値に基づくカベルゴリン治療：プロラクチノーマ管理における持続寛解と安全な妊娠の実現 https://news.medxy.ai/vi/cabergoline-prolactin-guided/Medxy AIvi2026-10-05T05:14:49-07:00Cabergoline cá thể hóa theo prolactin đáy: Nâng cao lui bệnh bền vững và an toàn thai kỳ trong điều trị prolactinoma https://news.medxy.ai/nadir-prolactin-guided-cabergoline-therapy-advancing-durable-remission-and-safe-pregnancy-in-prolactinoma-management/Medxy AIen2026-10-05T05:14:25-07:00Nadir Prolactin-Guided Cabergoline Therapy: Advancing Durable Remission and Safe Pregnancy in Prolactinoma Management https://news.medxy.ai/zh/baseline-plasma-metabolites/Medxy AIzh2026-10-05T05:13:47-07:00基线血浆代谢物可预测糖尿病前期长期血糖结局：来自 PROP-ABC 研究的启示 https://news.medxy.ai/ja/prediabetes-metabolites/Medxy AIja2026-10-05T05:13:23-07:00前糖尿病の長期血糖転帰を予測するベースライン血漿代謝物：PROP-ABC研究からの知見 https://news.medxy.ai/vi/plasma-metabolites-prediabetes/Medxy AIvi2026-10-05T05:13:00-07:00Các chất chuyển hóa huyết tương ban đầu dự báo kết cục đường huyết dài hạn ở tiền đái tháo đường: Kết quả từ nghiên cứu PROP-ABC https://news.medxy.ai/baseline-plasma-metabolites-predict-long-term-glycemic-outcomes-in-prediabetes-insights-from-the-prop-abc-study/Medxy AIen2026-10-05T05:12:39-07:00Baseline Plasma Metabolites Predict Long-Term Glycemic Outcomes in Prediabetes: Insights from the PROP-ABC Study https://news.medxy.ai/zh/tirzepatide-cardiovascular-benefits/Medxy AIzh2026-10-05T05:12:01-07:00替尔泊肽心血管获益再解析：基于 REWIND 推算安慰剂的 SURPASS-CVOT 间接比较 https://news.medxy.ai/ja/tirzepatide-cardiovascular-protection/Medxy AIja2026-10-05T05:11:42-07:00Tirzepatideの心血管保護作用を再考する：REWIND補完的プラセボ解析によるSURPASS-CVOTの知見 https://news.medxy.ai/vi/tirzepatide-heart-benefits/Medxy AIvi2026-10-05T05:11:19-07:00Tirzepatide hé lộ lợi ích tim mạch: bằng chứng từ SURPASS-CVOT với phân tích giả dược suy diễn của REWIND https://news.medxy.ai/unveiling-cardiovascular-benefits-of-tirzepatide-insights-from-surpass-cvot-using-imputed-placebo-analysis-of-rewind/Medxy AIen2026-10-05T05:11:00-07:00Unveiling Cardiovascular Benefits of Tirzepatide: Insights from SURPASS-CVOT Using Imputed Placebo Analysis of REWIND https://news.medxy.ai/zh/early-pregnancy-glucose/Medxy AIzh2026-10-05T05:10:22-07:00早孕血糖检测有助于提升妊娠期糖尿病预测：GO MOMs 研究带来新启示 https://news.medxy.ai/ja/gestational-diabetes-prediction/Medxy AIja2026-10-05T05:10:02-07:00妊娠初期の血糖評価で妊娠糖尿病をより高精度に予測：GO MOMs研究からの示唆 https://news.medxy.ai/vi/early-gestational-blood-sugar-test/Medxy AIvi2026-10-05T05:09:39-07:00Xét nghiệm đường huyết sớm trong thai kỳ giúp dự đoán đái tháo đường thai kỳ tốt hơn: Phân tích từ nghiên cứu GO MOMs https://news.medxy.ai/early-pregnancy-glycemic-testing-enhances-gestational-diabetes-prediction-insights-from-the-go-moms-study/Medxy AIen2026-10-05T05:09:18-07:00Early Pregnancy Glycemic Testing Enhances Gestational Diabetes Prediction: Insights from the GO MOMs Study https://news.medxy.ai/zh/80749-2/Medxy AIzh2026-10-05T05:08:39-07:00宫内暴露于母体糖尿病与子代糖尿病风险：原住民与非原住民群体间的差异 https://news.medxy.ai/ja/80748-2/Medxy AIja2026-10-05T05:08:19-07:00母親の糖尿病への子宮内曝露と次世代の糖尿病リスク：ファースト・ネーションズと非ファースト・ネーションズ間の差異 https://news.medxy.ai/vi/maternal-diabetes-exposure-risk/Medxy AIvi2026-10-05T05:07:53-07:00Phơi nhiễm đái tháo đường của mẹ trong tử cung và nguy cơ đái tháo đường ở thế hệ con: khác biệt giữa First Nations và không thuộc First Nations https://news.medxy.ai/in-utero-exposure-to-maternal-diabetes-and-its-impact-on-offspring-diabetes-risk-among-first-nations-and-non-first-nations-populations-a-comprehensive-review/Medxy AIen2026-10-05T05:07:28-07:00In Utero Exposure to Maternal Diabetes and Its Impact on Offspring Diabetes Risk among First Nations and Non-First Nations Populations: A Comprehensive Review https://news.medxy.ai/zh/low-dose-il2-diabetes/Medxy AIzh2026-10-05T05:06:38-07:00新诊断1型糖尿病中的低剂量白细胞介素-2：来自DIABIL-2 2b期试验的启示 https://news.medxy.ai/ja/low-dose-il2-type1-diabetes/Medxy AIja2026-10-05T05:06:22-07:00新規発症1型糖尿病における低用量インターロイキン2：DIABIL-2第2b相試験から得られた知見 https://news.medxy.ai/vi/80742-2/Medxy AIvi2026-10-05T05:06:02-07:00Sử dụng Interleukin-2 liều thấp ở bệnh nhân mới được chẩn đoán mắc đái tháo đường tuýp 1: Những thông tin từ thử nghiệm lâm sàng giai đoạn 2b DIABIL-2 https://news.medxy.ai/low-dose-interleukin-2-in-newly-diagnosed-type-1-diabetes-insights-from-the-diabil-2-phase-2b-trial/Medxy AIen2026-10-05T05:05:43-07:00Low-Dose Interleukin-2 in Newly Diagnosed Type 1 Diabetes: Insights from the DIABIL-2 Phase 2b Trial https://news.medxy.ai/zh/no-touch-vs-traditional-vein/Medxy AIzh2026-10-05T05:05:07-07:00冠脉搭桥中无接触法与传统静脉获取：SWEDEGRAFT七年随机试验解读 https://news.medxy.ai/ja/no-touch-cabg-results/Medxy AIja2026-10-05T05:04:42-07:00CABGにおける no-touch 法は本当に優れているのか？ SWEDEGRAFT試験が示した7年成績 https://news.medxy.ai/vi/no-touch-vein-harvesting/Medxy AIvi2026-10-05T05:04:18-07:00Kỹ thuật lấy tĩnh mạch no-touch hay thường quy trong CABG: Những phát hiện từ thử nghiệm ngẫu nhiên SWEDEGRAFT kéo dài 7 năm https://news.medxy.ai/no-touch-versus-conventional-vein-harvesting-in-coronary-bypass-surgery-insights-from-the-swedegraft-seven-year-randomized-trial/Medxy AIen2026-10-05T05:03:55-07:00No-Touch Versus Conventional Vein Harvesting in Coronary Bypass Surgery: Insights from the SWEDEGRAFT Seven-Year Randomized Trial https://news.medxy.ai/zh/80734-2/Medxy AIzh2026-10-05T05:03:13-07:00心力衰竭中的心血管-肾脏-代谢多病共存：患病率、对预后的影响及按射血分数表型划分的临床意义 https://news.medxy.ai/ja/heart-failure-multimorbidity/Medxy AIja2026-10-05T05:02:48-07:00心不全における心血管・腎臓・代謝の多疾患併存：有病率、予後への影響、駆出率表現型別の臨床的意義 https://news.medxy.ai/vi/cardiorenal-metabolic-failure/Medxy AIvi2026-10-05T05:02:19-07:00Đa bệnh lý tim mạch–thận–chuyển hóa trong suy tim: Tỷ lệ hiện mắc, ý nghĩa tiên lượng và hàm ý lâm sàng theo các kiểu hình phân suất tống máu https://news.medxy.ai/cardiovascular-kidney-metabolic-multimorbidity-in-heart-failure-prevalence-prognostic-impact-and-clinical-implications-across-ejection-fraction-phenotypes/Medxy AIen2026-10-05T05:01:54-07:00Cardiovascular-Kidney-Metabolic Multimorbidity in Heart Failure: Prevalence, Prognostic Impact, and Clinical Implications Across Ejection Fraction Phenotypes https://news.medxy.ai/zh/immunotherapy-liver-cancer/Medxy AIzh2026-10-05T05:01:02-07:00免疫检查点抑制剂助力肝细胞癌降期：证据、结局与临床启示 https://news.medxy.ai/ja/80728-2/Medxy AIja2026-10-05T05:00:41-07:00免疫チェックポイント阻害薬による肝細胞癌のダウンステージング：エビデンス、転帰、および臨床的示唆 https://news.medxy.ai/vi/80727-2/Medxy AIvi2026-10-05T05:00:17-07:00Các thuốc ức chế điểm kiểm soát miễn dịch hỗ trợ hạ giai đoạn ung thư biểu mô tế bào gan https://news.medxy.ai/immune-checkpoint-inhibitor-based-downstaging-therapy-for-hepatocellular-carcinoma-evidence-outcomes-and-clinical-perspectives/Medxy AIen2026-10-05T04:59:51-07:00Immune Checkpoint Inhibitor-Based Downstaging Therapy for Hepatocellular Carcinoma: Evidence, Outcomes, and Clinical Perspectives https://news.medxy.ai/zh/racial-ethnic-disparities-face-paralysis/Medxy AIzh2026-10-05T04:39:12-07:00面瘫中的种族与族裔差异：诊断、合并症与治疗不平等 https://news.medxy.ai/ja/facial-paralysis-disparities/Medxy AIja2026-10-05T04:38:52-07:00顔面麻痺における人種・民族差：診断、併存疾患、治療アクセスの格差 https://news.medxy.ai/vi/racial-ethnic-disparities-facial-paralysis/Medxy AIvi2026-10-05T04:38:33-07:00Chênh lệch theo chủng tộc và sắc tộc trong liệt mặt: chẩn đoán, bệnh đồng mắc và bất công trong điều trị https://news.medxy.ai/racial-and-ethnic-disparities-in-facial-paralysis-diagnosis-comorbidities-and-treatment-inequities/Medxy AIen2026-10-05T04:38:14-07:00Racial and Ethnic Disparities in Facial Paralysis: Diagnosis, Comorbidities, and Treatment Inequities https://news.medxy.ai/zh/neck-hematoma-hypocalcemia-risk/Medxy AIzh2026-10-05T04:37:35-07:00甲状腺切除术后颈部血肿提示更高低钙血症风险：基于全国外科数据库53,091例病例的研究洞见 https://news.medxy.ai/ja/neck-hematoma-hypocalcemia-risk-2/Medxy AIja2026-10-05T04:37:16-07:00甲状腺摘出術後の頸部血腫は低カルシウム血症リスクを高める：全国手術データベース53,091例からの知見 https://news.medxy.ai/vi/neck-hematoma-thyroidectomy/Medxy AIvi2026-10-05T04:36:55-07:00Máu tụ vùng cổ sau cắt tuyến giáp báo hiệu nguy cơ hạ calci máu cao hơn: Phân tích từ 53.091 ca trong cơ sở dữ liệu phẫu thuật quốc gia https://news.medxy.ai/post-thyroidectomy-neck-hematoma-predicts-higher-risk-of-hypocalcemia-insights-from-53091-cases-in-a-national-surgical-database/Medxy AIen2026-10-05T04:36:36-07:00Post-Thyroidectomy Neck Hematoma Predicts Higher Risk of Hypocalcemia: Insights from 53,091 Cases in a National Surgical Database https://news.medxy.ai/zh/rectal-cancer-lymph-node-management/Medxy AIzh2026-10-05T04:35:50-07:00直肠癌TNT后侧盆腔淋巴结降期患者的管理策略：是否仍需一味手术清扫？ https://news.medxy.ai/ja/lateral-pelvic-lymph-nodes/Medxy AIja2026-10-05T04:35:30-07:00全補助療法後にダウンステージングされた直腸癌の側方骨盤リンパ節：管理戦略の再考 https://news.medxy.ai/vi/pelvic-lymph-node-management/Medxy AIvi2026-10-05T04:35:08-07:00Tái đánh giá chiến lược xử trí hạch bạch huyết chậu bên đã giảm giai đoạn trong ung thư trực tràng dưới liệu pháp tân bổ trợ toàn diện https://news.medxy.ai/reevaluating-management-strategies-for-downstaged-lateral-pelvic-lymph-nodes-in-rectal-cancer-under-total-neoadjuvant-therapy/Medxy AIen2026-10-05T04:34:49-07:00Reevaluating Management Strategies for Downstaged Lateral Pelvic Lymph Nodes in Rectal Cancer under Total Neoadjuvant Therapy